Deutsche Bank AG Increases Stock Position in AbbVie Inc. $ABBV

Deutsche Bank AG lifted its stake in AbbVie Inc. (NYSE:ABBV) by 13.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,772,949 shares of the company’s stock after acquiring an additional 1,241,587 shares during the quarter. AbbVie accounts for about 0.8% of Deutsche Bank AG’s investment portfolio, making the stock its 18th largest holding. Deutsche Bank AG’s holdings in AbbVie were worth $2,710,905,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in ABBV. Capital Advisors Inc. OK lifted its holdings in AbbVie by 11.2% in the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock valued at $112,516,000 after acquiring an additional 45,132 shares during the period. Ranch Capital Advisors Inc. increased its position in shares of AbbVie by 37.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock valued at $3,238,000 after purchasing an additional 4,017 shares during the last quarter. Wedge Capital Management L L P NC lifted its stake in shares of AbbVie by 7.5% in the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after purchasing an additional 9,380 shares during the period. Mission Wealth Management LP lifted its stake in shares of AbbVie by 119.1% in the 2nd quarter. Mission Wealth Management LP now owns 69,052 shares of the company’s stock worth $17,376,000 after purchasing an additional 37,531 shares during the period. Finally, ABN Amro Investment Solutions boosted its holdings in shares of AbbVie by 173.5% in the second quarter. ABN Amro Investment Solutions now owns 649,098 shares of the company’s stock worth $163,339,000 after buying an additional 411,780 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ABBV has been the topic of several recent research reports. Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target on the stock in a research report on Thursday, August 13th. Guggenheim upped their price objective on AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Wells Fargo & Company boosted their price target on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a report on Monday, August 17th. Finally, Cantor Fitzgerald upped their price target on AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $275.95.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of SKYRIZI in adults with moderately to severely active Crohn’s disease. The filing, supported by positive Phase 3 AFFIRM data, could expand SKYRIZI’s European Crohn’s disease label and offer patients a less invasive alternative to intravenous induction. AbbVie Submits Regulatory Application to EMA for SKYRIZI Subcutaneous Induction
• Positive Sentiment: The company’s inclusion in articles highlighting reliable dividend stocks reinforces AbbVie’s appeal to income-focused investors. Its dividend profile and defensive healthcare exposure may provide support, particularly during periods of economic or inflation uncertainty. 3 Dividend Stocks, 12 Paychecks a Year
• Positive Sentiment: Ken Griffin reportedly increased his AbbVie stake by 547% during the second quarter, signaling confidence from a prominent institutional investor in the company’s dividend and long-term prospects. Ken Griffin Increased His Stake in AbbVie
• Neutral Sentiment: AbbVie’s patient-support efforts, including an immunology scholarship program, strengthen its public-facing support initiatives but are unlikely to materially affect near-term earnings or valuation. AbbVie’s Immunology Scholarship Program
• Negative Sentiment: Valuation concerns may be limiting upside. AbbVie has rallied significantly and is trading at a premium, prompting debate over whether future growth from SKYRIZI and the broader pipeline can justify the stock’s price. Has AbbVie Stock Become Too Expensive to Buy?

AbbVie Trading Down 1.8%

Shares of ABBV opened at $258.23 on Friday. The business’s 50 day moving average is $251.87 and its 200 day moving average is $228.68. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47. The company has a market capitalization of $456.24 billion, a PE ratio of 72.95, a price-to-earnings-growth ratio of 0.87 and a beta of 0.30.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period last year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts predict that AbbVie Inc. will post 14.06 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s dividend payout ratio is 195.48%.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.